Abstract 1122‐000110: Transvenous Embolization in Vein of Galen Malformations as the Last Procedure

2021 ◽  
Vol 1 (S1) ◽  
Author(s):  
Tomoyoshi Shigematsu ◽  
Stavros Matsoukas ◽  
Maximilian Bazil ◽  
Johanna Fifi ◽  
Alejandro Berenstein
Keyword(s):  
Clinical Outcomes ◽  
Final Stage ◽  
Transarterial Embolization ◽  
Treatment Method ◽  
Neurological Impairment ◽  
Arterial Supply ◽  
Vein Of Galen ◽  
Transvenous Embolization ◽  
Eligibility Criteria ◽  
Hemorrhagic Complications

Introduction : Vein of Galen Malformations (VOGM) are a rare, congenital, vascular malformation representing <1% of all arteriovenous malformations. Treatment is typically performed in infancy and transarterial embolization (TAE) is the most common treatment method. While conventional methods allow for a total or near‐total obliteration in 80% of cases, there is a subset of patients for whom TAE is ineffective (E.g. the residual arterial supply is through small feeders non‐amenable to TAE). In these cases, transvenous embolization or coiling (TVE) is the technically simplest approach. We assessed the immediate angiographic and clinical outcomes of our VOGM cases treated with TVE. All relative technical details are reported. Immediate angiographic outcomes and clinical outcomes are reported. Methods : A retrospective review of our institutional database was performed to identify all VOGM patients who underwent TVE as the final‐stage procedure between January 2004 and December 2020. Results : We describe a cohort of 13 patients, one of whom underwent partial TVE for palliative measures and was excluded. All of the 12 patients that met our eligibility criteria had undergone more than 3 transarterial embolizations with nBCA. The mean age of our cohort was 8.2 (SD: 6.3) years. Ten patients were treated with coils and two with the Chapot “Pressure cooker” (ChPC) Technique. In these two cases, predicting hemorrhage post‐procedurally proved difficult; as a result, we attempted to occlude the remaining arterial supply using transvenous ChPC. Complete immediate angiographic obliteration was achieved in nine patients. Stereotactic radiosurgery was performed in 2 of the remaining patients and full obliteration was achieved. Immediate post‐procedural (within 48 hours) hemorrhagic complications were noted in two patients treated with coils: one of these ended in mortality and the second suffered from significant neurological impairment. In total, eight patients had normal development, three had a moderate delay with hemiparesis and one patient died. Conclusions : To the best of our knowledge, this is the first report of TVE being used as a final‐stage cure attempt for VOGMs after multiple TAE sessions. We advocate that TVE for the treatment of VOGMs is a feasible option as a final‐stage attempt for cure. It is particularly effective if the dilated VOG becomes small enough. To prevent incomplete occlusion and reduce the risk of post‐procedural hemorrhagic complications, the ChPC technique using liquid embolic material should be considered.

Abstract 1122‐000045: Transvenous Embolization of Vein of Galen Aneurismal Malformations Using the “Chapot Pressure Cooker” Technique

2021 ◽  
Vol 1 (S1) ◽  
Author(s):  
Maximilian J Bazil ◽  
Tomoyoshi Shigematsu ◽  
Maximilian J Bazil ◽  
Stavros Matsoukas ◽  
Johanna T Fifi ◽  
...  
Keyword(s):  
Transarterial Embolization ◽  
Arterial Supply ◽  
Vein Of Galen ◽  
Transvenous Embolization ◽  
Newborn Period ◽  
Embolic Material ◽  
First Report ◽  
Delayed Bleeding ◽  
Complete Closure ◽  
Liquid Embolic

Introduction : There are various procedural techniques described in the literature to treat VGAM: 1) transarterial embolization (TAE) via a transfemoral or transumbilical approach, 2) transfemoral or transtorcular venous coiling, and 3) the combined transarterial and transvenous “trapping” of the fistula. The transarterial technique has permitted our team to obtain total or near‐total obliteration in approximately 80% of cases; however, there is a patient population in whom the residual arterial supply is comprised of small perforators. In these patients, transvenous embolization (TVE) is an attractive option, but its safety is unclear. Here we report the first two VGAM patients treated using the Chapot “pressure cooker” technique (ChPC). Methods : Two patients, one 5‐year‐old and one 7‐year‐old, both presented with congestive heart failure in the newborn period and were subsequently treated in the newborn period with multiple, staged TAEs with n‐BCA for choroidal VGAMs. We achieved progressive reduction in shunting and flow but were unable to accomplish complete closure of the malformation: in both patients, a small residual with numerous perforators persisted. The decision was made to perform transvenous embolization using the CHPC. In this technique, a guiding catheter is placed transjugular into the straight sinus (SS). One or two detachable tip microcatheters are advanced to the origin of the SS. Another microcatheter is advanced and the tip placed between the distal marker and the detachment zone of the former. Coils, and n‐BCA if necessary, are used to prevent reflux of Onyx. This forces the Onyx to occlude the vein and the most distal arterial segment. Results : Both patients had complete occlusion of the VGAM after ChPC. Conclusions : This is the first report to describe TVE to cure VGAM after multiple sessions of TAE. This is also the first report to apply ChPC to VGAM treatment. In this study, we recognized two important factors of traditional VGAM treatment that may cause interventionalists to consider the ChPC to treat VGAM: 1) without liquid embolic, deployed coils may not occlude the fistula entirely. 2) There is the concern of causing delayed bleeding should the arterial component of the fistula rupture. ChPC ameliorates these issues by offering complete closure of the fistula with liquid embolic material in TVE. Not only is the residual vein blocked, but also the incoming arterial supply which prevents delayed bleeding. In endovascular treatment of VGAM, TVE is feasible option once the dilated vein of Galen becomes small enough. To prevent incomplete occlusion or post‐procedural hemorrhagic complications, the use of the ChPC using DMSO liquid embolic material is a promising and necessary introduction to the neurointerventionalist’s treatment arsenal.

scholarly journals The Prognosis for Fetuses with Vein of Galen Malformation and Symptoms of Heart Failure

2017 ◽  
Vol 7 (1) ◽  
pp. 83-87
Author(s):  
Agnieszka Nawara-Baran
Keyword(s):  
Heart Failure ◽  
Transarterial Embolization ◽  
Volume Overload ◽  
Mass Effect ◽  
Neurological Impairment ◽  
Cardiac Insufficiency ◽  
Neurological Deficits ◽  
Vein Of Galen ◽  
Vein Of Galen Malformation ◽  
Flow Through

Abstract Vein of Galen Malformation (VGM) it is the most common cerebral arteriovenus malformation in fetuses and children. Usually VGM causes volume overload of the heart and can induce mass effect in the brain, causing progressive neurological impairment. Modern treatment allow on earlier therapy (before the 5th monthof life). This gives the newborn with isolated VGM and heart failure a chance of survival. This work presents case of isolated vein of Galen malformation with diagnosed cardiomegaly, monophasic flow through the tricuspid valve, large right heart, pericardiac effusion, dilatation of SVC and abnormal doppler exam. Postnatal management included aggressive medical treatment of cardiac failure and early transarterial embolization of the selected vessels feeding the aneurysm at 6 days of age. The newborn is 6 month old, growing normally without neurological deficits or developmental retardation and waiting of next stage therapy. New techniques of treatment give fetuses with VGM and prenatal signs of cardiac insufficiency a chance of survival and healthy life, in a group of selected cases. The analysis of the cardiovascular system in fetuses with VGM according to uniform criteria is essential in order to assess the influence of these malformations on the survivability of newborns.

Transarterial embolization of peripheral arteriovenous malformations with ethylenevinyl alcohol copolymer - feasibility, technical outcomes, and clinical outcomes

VASA ◽  
2016 ◽  
Vol 45 (6) ◽  
pp. 497-504 ◽  
Author(s):  
Tom De Beule ◽  
Jan Vranckx ◽  
Peter Verhamme ◽  
Veerle Labarque ◽  
Marie-Anne Morren ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Clinical Improvement ◽  
Arteriovenous Malformations ◽  
Clinical Success ◽  
Transarterial Embolization ◽  
Recurrent Bleeding ◽  
Complete Disappearance ◽  
Ethylene Vinyl Alcohol ◽  
Initial Symptoms

Abstract. Background: The technical and clinical outcomes of catheter-directed embolization for peripheral arteriovenous malformations (AVM) using Onyx® (ethylene-vinyl alcohol copolymer) are not well documented. The purpose of this study was to retrospectively assess the safety, technical outcomes and clinical outcomes of catheter-directed Onyx® embolisation for the treatment of symptomatic peripheral AVMs. Patients and methods: Demographics, (pre-)interventional clinical and radiological data were assessed. Follow-up was based on hospital medical records and telephone calls to the patients’ general practitioners. Radiological success was defined as complete angiographic eradication of the peripheral AVM nidus. Clinical success was defined as major clinical improvement or complete disappearance of the initial symptoms. Results: 25 procedures were performed in 22 patients. The principal indications for treatment were pain (n = 10), limb swelling (n = 6), recurrent bleeding (n = 2), tinnitus (n = 3), and exertional dyspnoea (n = 1). Complete radiological success was obtained in eight patients (36 %); near-complete eradication of the nidus was achieved in the remaining 14 patients. Adjunctive embolic agents were used in nine patients (41 %). Clinical success was observed in 18 patients (82%). Major complications were reported in two patients (9 %). During follow-up, seven patients (32 %) presented with symptom recurrence, which required additional therapy in three patients. Conclusions: Catheter-directed embolisation of peripheral AVMs with Onyx® resulted in major clinical improvement or complete disappearance of symptoms in the vast majority of patients, although complete angiographic exclusion of the AVMs occurred in only a minority of patients.

scholarly journals 1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S794-S794
Author(s):  
Ryan J Dillon ◽  
Zarmina S Khankhel ◽  
Carisa De Anda ◽  
Christopher Bruno ◽  
Laura A Puzniak
Keyword(s):  
Clinical Outcomes ◽  
Clinical Success ◽  
Complicated Urinary Tract Infection ◽  
Clinical Trial Data ◽  
Empiric Therapy ◽  
Multidrug Resistant ◽  
Eligibility Criteria ◽  
Published Evidence ◽  
Gram Negative Bacteremia ◽  
Intra Abdominal Infection

Abstract Background Bacteremia is a significant cause of morbidity and mortality. Several studies have shown this burden to increase among patients with multidrug resistant (MDR) PSA, and in those treated with inappropriate empiric therapy. Ceftolozane/tazobactam (C/T) is a combination of a novel antipseudomonal cephalosporin and an established β-lactamase inhibitor approved for the treatment of complicated urinary tract infection, complicated intra-abdominal infection and hospital-acquired and ventilator-associated bacterial pneumonia. In the absence of specific bacteremia clinical trial data; the aim of this study is to describe all published evidence relating to C/T for the treatment of Gram negative bacteremia. Methods This SLR includes all published evidence from December 2015 to March 2020 searched via the OVID platform: EMBASE, MEDLINE, and MEDLINE In-Process. In addition, data published (2018-2019) from the European Society of Clinical Microbiology and Infectious Diseases and Infectious Disease Week Congresses were included. Eligible publications were on adult patients treated with C/T reporting any clinical outcome where data were reported specifically for the bacteremia population. Results The SLR identified 1,455 citations, of which 24 publications representing 23 unique studies met eligibility criteria. This included primary and secondary bacteremia. Ten studies included patients with primary bacteremia, only 7 of which reported results specific to primary bacteremia patients. Despite heterogeneity in study design, patient and treatment characteristics, and a lack of detailed reporting; the majority of studies focused on MDR/ extensively drug resistant (XDR) infections (range: 68.3%-100%). Clinical success/ cure ranged from 33%-100%, with 6/7 studies at &gt;85%; 30-day mortality from 0%-67%, with 3/7 studies at 0% (Table 1). Table 1. Clinical Outcomes reported among Primary Bacteremia population(s) Conclusion Although the number of C/T treated patients was small, favorable clinical outcomes were observed, even among highly resistant PSA infections. Heterogeneity was ubiquitous, with diverse and complex patient profiles identified. Further studies where outcomes are stratified by bacteremia status and by timing of C/T treatment are needed. Disclosures Ryan J. Dillon, MSc, Merck & Co., Inc., (Employee) Carisa De Anda, PharMD, Merck & Co Inc, (Employee) Christopher Bruno, MD, Merck & Co., Inc. (Employee) Laura A. Puzniak, PhD, Merck (Employee)

scholarly journals 270. Clinical Outcomes of Ceftriaxone versus Penicillin G for Complicated Viridans Group Streptococci Bacteremia

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S137-S137
Author(s):  
Stephanie Wo ◽  
Yanina Dubrovskaya ◽  
Justin Siegfried ◽  
John Papadopoulos ◽  
Shin-Pung Jen
Keyword(s):  
Clinical Outcomes ◽  
Hospital Readmission ◽  
Protective Factor ◽  
Primary Outcome ◽  
Bloodstream Infections ◽  
Penicillin G ◽  
Eligibility Criteria ◽  
Extended Spectrum Beta Lactamase ◽  
Increased Risk ◽  
Viridans Group Streptococci

Abstract Background Viridans group streptococci (VGS) is an infrequent yet significant cause of bloodstream infections, and complicated cases may require prolonged antibiotic therapy. Ceftriaxone (CTX) and penicillin G (PCN G) are both considered first line options for VGS infections, but comparisons between these agents are limited. We evaluated the clinical outcomes amongst patients treated with CTX and PCN G for complicated VGS bacteremia. Methods This was a single-center, retrospective study of adult patients with ≥1 positive VGS blood culture who were treated with either CTX or PCN G/ampicillin (both included in PCN G arm) between January 2013 and June 2019. The primary outcome was a composite of safety endpoints, including hospital readmission due to VGS or an adverse event (AE) from therapy, Clostridioides difficile infections, treatment modification or discontinuation due to an antibiotic-related AE, and development of extended-spectrum beta lactamase resistance. Secondary outcomes included the individual safety endpoints, VGS bacteremia recurrence, hospital readmission, and all-cause mortality. Results Of 328 patients screened for inclusion, 94 patients met eligibility criteria (CTX n= 64, PCN G n=34). Median age was 68 years (IQR 56–81) and 68% were male. Study patients did not present with critical illness, as reflected by a median Pitt bacteremia score of 0 in the CTX and 1 in the PCN G arms, P=0.764. Streptococcus mitis was the most common VGS isolate and infective endocarditis (IE) was the predominant source of infection. CTX was not significantly associated with increased risk of the primary outcome (14% vs. 27%; P= 0.139). The driver of the composite outcome was hospital readmission due to VGS bacteremia or therapy complications. Results were similar in the subgroup of patients with IE (12.5% vs. 23.5%). No secondary endpoints differed significantly between groups. On multivariate analysis, source removal was a protective factor of the primary outcome (OR 0.1; 95% CI 0.020–0.6771; P= 0.017). Conclusion Despite potential safety concerns with the prolonged use of CTX in complicated VGS bacteremia, this study did not demonstrate a higher rate of treatment failure, adverse events, or resistance. These findings warrant further exploration. Disclosures All Authors: No reported disclosures

Healing Pattern of Thoracolumbar Burst Fracture after Posterior Short-segmental Fixation

2020 ◽  
Author(s):  
Changxiang Liang ◽  
Guihua Liu ◽  
Guoyan Liang ◽  
Xiaoqing Zheng ◽  
Dong Yin ◽  
...  
Keyword(s):  
Risk Factor ◽  
Clinical Outcomes ◽  
Burst Fracture ◽  
Neurological Impairment ◽  
Complete Healing ◽  
Smoking History ◽  
Thoracolumbar Burst Fractures ◽  
Burst Fractures ◽  
History Of ◽  
Segmental Fixation

Abstract Background: Vertebral cavity sometimes occurs after posterior short-segmental fixation for thoracolumbar burst fractures, but the risk factor of its formation is unclear. We aim to investigate their vertebral healing pattern and explore the risk factor of vertebral cavities.Methods: The thoracolumbar burst fractured patient treated with posterior short segmental fixation were followed up for minimal 3 years. Healing patterns were observed and divided into 4 healing types according to the integrity status of the endplates and the morphology of the cavities. The demographic characteristics and clinical outcomes were compared between patients with and without vertebra cavities at the last follow-up.Results: The incidence of vertebral cavities in our cohort was 59.6%. Accordingly, the healing pattern of the vertebra were classified as Complete Healing type or Endplate Cavity type, Spherical Cavity type or Burst Cavity type. The proportion of men, history of smoking, severity of neurological impairment and presence of A4 type fracture were significantly higher in the Vertebral Cavity group than the Intact Vertebra group. Clinical outcomes, including ASIA scales,VAS and ODI scores, were similar between the Intact Vertebra group and the Vertebral Cavity group. Conclusions: Vertebral cavities are commonly seen after posterior short-segmental fixation for thoracolumbar burst fractures. The healing pattern can be divided into four types. The presence of vertebral cavity may be related to gender, smoking history and the severity of the fracture. Most of the vertebral cavities are asymptomatic, but the clinical significance needs further study.

scholarly journals Transvenous Embolization for Dural Arteriovenous Shunt of the Cavernous Sinus

2007 ◽  
Vol 13 (4) ◽  
pp. 353-358 ◽  
Author(s):  
S. Kato ◽  
H. Ishihara ◽  
H. Nakayama ◽  
M. Fujii ◽  
H. Fujisawa ◽  
...  
Keyword(s):  
Arteriovenous Fistula ◽  
Cavernous Sinus ◽  
Cranial Nerve ◽  
Dural Arteriovenous Fistula ◽  
Clinical Symptoms ◽  
Transarterial Embolization ◽  
Arteriovenous Shunt ◽  
Complete Disappearance ◽  
Transvenous Embolization ◽  
Arteriovenous Shunts

We describe the treatment and follow-up clinical symptoms and angiographic results in patients with dural arteriovenous fistula of the cavernous sinus treated by transvenous embolization (TVE). We have treated eight cases of dural arteriovenous fistula of the cavernous sinus by multi-staged TVE in two cases and TVE with sinus packing in six and three of six cases were treated with a combination of transarterial embolization. Multi-staged TVE was performed by occlusion from dangerous drainage veins to the cavernous sinus on several occasions. Angiographical results showed disappearance or reduction of the arteriovenous shunt in all cases. Six patients presented with ophthalmic symptoms and two had tinnitus. Six cases had complete disappearance of clinical symptoms after treatment. There was a deterioration of ocular movement in one patient treated by TVE with sinus packing. Multi-staged TVE was performed to reduce the coil volume for the packing of the cavernous sinus in two cases without cranial nerve palsy. Embolization, especially multi-staged TVE, was considered a good treatment to occlude arteriovenous shunts at the cavernous sinus without cranial nerve complications.

The Management of Vein of Galen Aneurysmal Malformations

Neurosurgery ◽  
2006 ◽  
Vol 59 (suppl_5) ◽  
pp. S3-184-S3-194 ◽  
Author(s):  
Pierre L. Lasjaunias ◽  
Soke M. Chng ◽  
Marina Sachet ◽  
Hortensia Alvarez ◽  
Georges Rodesch ◽  
...  
Keyword(s):  
Arteriovenous Malformation ◽  
Normal Growth ◽  
Venous Drainage ◽  
Treatment Method ◽  
Growth Conditions ◽  
Endovascular Embolization ◽  
Therapeutic Window ◽  
Vein Of Galen ◽  
Neurologically Normal ◽  
Level Of Understanding

Abstract OBJECTIVE: The vein of Galen aneurysmal malformation (VGAM) is a choroidal type of arteriovenous malformation involving the vein of Galen forerunner. This is distinct from an arteriovenous malformation with venous drainage into a dilated, but already formed, vein of Galen. Reports of endovascular treatment of VGAM in the literature approach the disease from a purely technical viewpoint and often fail to provide satisfactory midterm results. To focus the therapeutic challenge to a strictly morphological goal overlooks the fundamental aspects of neonatal and infant anatomy and fluid physiology. During the past 20 years, our approach to VGAM has remained the same. Our experience, based on 317 patients with VGAM who were studied in Hospital Bicêtre between October 1981 and October 2002, allows us to describe the angioarchitecture, natural history, and management of VGAM in neonates, infants, and children. METHODS: Of our cohort of 317 patients, 233 patients were treated with endovascular embolization; of these, 216 patients were treated in our hospital. The treatment method of choice was a transfemoral arterial approach to deliver glue at the fistulous zone. RESULTS: Of 216 patients, 23 died despite or because of the embolization (10.6%). Twenty out of the 193 (10.4%) surviving patients were severely retarded, 30 (15.6%) were moderately retarded, and 143 (74%) were neurologically normal on follow-up. CONCLUSION: Our data demonstrate that most treated children survive and undergo normal neurological development; an understanding of the clinical, anatomical, and pathophysiological features of VGAM has, therefore, reversed the former poor prognosis. Our level of understanding about the lesion allows us to predict most situations and remedy them by applying a strict evaluation protocol and working within an optimal therapeutic window. Patient selection and timing remain the keys in the management of this condition. It is more important to restore normal growth conditions than a normal morphological appearance, with the primary therapeutic objective being normal development in a child without neurological deficit.

Sign in / Sign up

Export Citation Format

Share Document